Market News
3 min read | Updated on January 09, 2025, 12:20 IST
SUMMARY
Standard Glass Lining IPO allotment status is expected to be finalised on Thursday, January 9, after a robust subscription. Investors can check finalisation information on the websites of Kfin Technologies Limited, the NSE, and the BSE.
Shares of Standard Glass Lining will debut in the secondary market on Monday, January 13.
Standard Glass Lining IPO allotment: The share allotment status of Standard Glass Lining Technology Ltd will be finalised on Thursday, January 9, 2025. The issue got an overwhelming response across the investor categories.
The ₹410.05-crore initial share sale received bids for 3,81,56,56,808 shares against 2,08,29,567 equity shares on offer, according to data on the NSE website.
Qualified institutional buyers led the demand, as their quota was subscribed a stellar 331.60 times. They placed bids for 1,91,99,91,629 shares against 57,90,147 shares on offer.
The non-institutional investors' category got 268.50 times subscription, as they bid for 1,21,14,47,259 shares compared to 45,11,826 shares on offer.
The retail individual investors' portion was booked 64.99 times, as they placed bids for 68,42,17,920 equity shares against 1,05,27,594 shares reserved.
Shares of Standard Glass Lining will debut in the secondary market on Monday, January 13. The stock will be listed on the BSE and the National Stock Exchange (NSE) at 10 am.
The public issue consisted of new equity shares worth ₹210 crore and an offer for sale component of up to 1.43 crore shares. It had fixed a price band of ₹133 to ₹140 per share. The lot size was 107 shares.
Proceeds to the tune of ₹130 crore will be earmarked for debt repayment, ₹20 crore for organic growth via acquisitions or strategic investments, ₹10 crore for machinery purchases, and ₹30 crore for investment in the subsidiary S2 Engineering Industry. A part will also be used for corporate general purposes.
Standard Glass Lining Technology is a comprehensive solutions provider from design, engineering and manufacturing to installation, commissioning and establishing SOPs for chemical and pharmaceutical manufacturers on a turnkey basis.
Its clients include Cadila Pharmaceutical, Aurobindo Pharma, Granules India Ltd, Piramal Pharma, Suven Pharmaceuticals and Macleods Pharmaceuticals.
Motilal Oswal Investment Advisors Ltd and IIFL Capital Services Ltd (formerly IIFL Securities Ltd) were the book-running lead managers for the issue.
Particulars | FY22 | FY23 | FY24 | H1FY25 |
---|---|---|---|---|
Revenue | ₹240.19 cr | ₹497.59 cr | ₹543.67 cr | ₹307.20 cr |
Net Profit | ₹25.15 cr | ₹53.42 cr | ₹60.01 cr | ₹36.27 cr |
About The Author
Next Story